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ABSTRACT (100/100 Words) 
The research on extracellular vesicles (EVs) has been exponentially rising during the past few 
years. EVs are found in different biofluids and are potential sources for the discovery of novel 
biomarkers. In this review, we demonstrate a conceptual overview of the field and current 
knowledge, critically assess the new advances in the field of EV biomarkers, and discuss 
different challenges to validate and implement EVs as clinical diagnostics. Future 
implementation of ‘omics-based technologies and integration of systems biology approaches for 
the development of EV-based biomarkers and personalized medicine are also considered.  
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Extracellular vesicles (EV) were historically considered to be membrane-derived cellular debris 
with no biological or clinical significance produced during cell death. However, evidence is 
amassing that EVs can exert multiple physiological and pathological functions as important 
mediators of intercellular communications 1-3. Thus, such particles have been isolated from 
almost all cell types, mucosal and endogenous biofluids (blood, urine, saliva, cerebrospinal fluid, 
lymph, etc.) and have been implicated in key processes such as growth and development, cell-to-
cell communication, immunomodulation, blood coagulation, and various stages of tumorigenesis 
4-8. Table 1 and Table 2 exemplify EVs isolated from different cellular sources and biofluids.  
Diverse molecular cargoes have been recovered from EVs, such as nucleic acids, proteins, and 
lipids. Notably, these cargoes appear to be protected against degrading enzymes such as 
nucleases and proteases: protection is afforded by a natural lipid bilayer capsule derived from the 
cytosolic membrane of the originating cell shedding the EV 1,9-12. Importantly, much like 
synthetic liposomal micro and nanoparticles, the EV lipid bilayer and its enclosed cargo are 
stable under physicochemical conditions generally considered adverse for biological materials, 
such as long-term storage, multiple freeze-thaw cycles, and extreme pH 13. Several groups have 
shown that pathological states such as oxidative stress, transformation, apoptosis, and ethanol-
induced cell injury induce cells to increase their EV release rate, simultaneously altering their 
composition to reflect the altered state of the cellular origin 3,14-18. Together, these characteristics 
position EVs as a new, highly appealing class of biomarkers with strong diagnostic potential in 
the context of personalized medicine 19,20. This review explores in depth the potential of EVs as 
biomarkers of clinical utility. Current knowledge of EV subtypes, their biogenesis, and 
pathophysiological role are outlined, with emphasis placed on advantages against competing 
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analytes. Challenges to achieving the diagnostic potential of EVs including sample handling, EV 
isolation, method standardization, and bioassay reproducibility are discussed. These features will 
be presented in the context of systems biology and personalized medicine, two relatively new but 
rapidly expanding and unifying fields relevant to therapeutics innovation.  
 
Extracellular vesicles: subtypes and mechanisms of biogenesis 
The term ‘EV’ collectively refers to a heterogeneous vesicular population spanning  50 to 10,000 
nm in size (Box1). Distinct subpopulations include exosomes, microvesicles/microparticles, and 
apoptotic bodies 21,22, although the terms not associated with cell death have been used 
interchangeably in the past16, 34. These EVs are secreted from almost all cell types into the 
aqueous extracellular microenvironment and represent a snapshot of the cell status at the time of 
release, as defined by their components 3,23. Beyond size, which is itself inadequate 24, 
morphological characteristics such as density, mode of biogenesis, and molecular markers such 
as CD63, CD81 and Annexin V are used to classify EVs as outlined in Box1.   
Exosomes are the smallest (30 nm-100 nm) and most heavily studied subpopulation of EVs 25,26. 
These particles are generated by the exocytosis of multivesicular bodies (MVBs) 27,28 (Figure  
1). Early endosomes can be targeted for ubiquitin-dependent interactions with one of three 
endosomal sorting complexes required for transport (ESCRT-0, ESCRT-I and ESCRT-II), 
leading to recycling of the endosome or, alternatively, its progression towards a late endosomal 
pathway 29. Late endosomal pathways are dependent on MVBs, are ubiquitin-independent, and 
lead to the formation and sorting of exosomes 30. In this pathway, ALIX (ALG-2-interacting 
protein X) binding to the exosomal cargo molecules, can drive MVB to go through exosomal 
sorting pathways instead of lysosomal recycling pathways 31. While ESCRT complexes are 
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clearly required for the lysosomal degradation of proteins, their contribution to exosome 
formation is less well studied 32. However, selected ESCRT components and accessory proteins 
such as Signal Transducing Adaptor Molecule 1(STAM1), Tumor Susceptibility 101(TSG101), 
and hepatocyte growth factor-regulated tyrosine kinase substrate (HRS) are involved in exosome 
biogenesis machinery 33. The Rab GTPase family regulates fusion of late-endosomal MVBs with 
the plasma membrane and exosome release 34. Thus, Rab5 and Rab7 regulate endocytic 
trafficking downstream of MVB biogenesis and cargo sequestration whereas Rab27a, Rab27b, 
and Rab35 control exosome secretion 31,34,35.  
Microvesicles (also called shedding vesicles, shedding microvesicles, or microparticles) are 
approximately 100-1000 nm in diameter and originate from the outward budding of the plasma 
membrane 21. The protein TSG101, which is also involved in exosome biogenesis, interacts with 
arrestin domain-containing protein 1 in the budding stage of microvesicles 36. The release of both 
exosomes and microvesicles is associated with a specific region of the plasma membrane 
enriched in cholesterol, lipid rafts, and ceramide 13,37-39. Unlike endosome maturation, the small 
GTP-binding protein ARF6, the Rho signaling pathway, actin motors, and elements of the 
cytoskeleton are involved in the formation of microvesicles 40-42.  
Apoptotic vesicles are a subpopulation of  EVs that range from 100-2000 nm in diameter and are 
generated by the blebbing of plasma membrane of cells undergoing apoptosis. Larger apoptotic 
vesicles (1000-5000 nm) are referred to as apoptotic bodies and contain fragmented nuclei as 
well as fragmented cytoplasmic organelles 6,7. Importantly, the uptake of apoptotic bodies 
originating from tumor cells can transfer oncogenic contents to the recipient cells 18. For 
example, apoptotic bodies derived from rat embryonic fibroblasts carrying H-rasV12 and human 
c-myc oncogenes were internalized by recipient cells (mouse embryonic fibroblasts), resulting in 
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loss of contact inhibition in vitro and tumorigenic phenotype in vivo. Fluorescence in situ 
hybridization analysis, revealed the presence of rat and mouse fusion chromosomes in the nuclei 
of the recipient murine cells, propagation of aneuploidy and the accumulation of genetic changes 
necessary for tumor formation 18.  
The classification of extracellular vesicles can be based on size, density, protein composition, 
and cell specific markers 43,44. One of these parameters may not be adequate alone, however, as, 
for example, vesicles originating from different biogenesis pathways might have overlapping 
diameter ranges 24. Thus, the terminology referring to exosomes and extracellular vesicles has 
changed substantially over the past decade and the words “exosomes”, “microvesicles”, and 
“microparticles” have been used interchangeably in the past 21,43. Gaining a better understanding 
of vesicle formation led to the characterization of extracellular vesicles based on mode of origin. 
Nevertheless, current understanding of EV biogenesis is incomplete and further confounded by 
inconsistencies in EV isolation and characterization protocols. However, the identification of 
vesicles by specific molecular patterns, is expected to progressively deepen characterization of 
these biological products under refined, universally agreed criteria will lead to more advanced 
models of EV classification. The presently understood roles of EVs in the pathogenesis of 
disease is summarized in Table 3. 
 
EVs as biomarkers: promises and pitfalls 
The National Institutes of Health define the term biomarker as “a characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention” 45. In this context, the data deluge 
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obtained through comprehensive profiling of the genome, transcriptome, proteome, and 
metabolome in health and disease has catalyzed a paradigm shift on how basic biomedical 
research is conducted. Crucially, these data have repeatedly hinted at the potential for early, 
accurate disease diagnosis with high sensitivity. Personalized disease progression monitoring  
might also be achievable through identification or measurement of one or more of these 
biomarker classes- so called ‘biomarker signatures’. In this respect, the promise of EVs is 
growing exponentially (Figure 2).     
Liquid biopsy for EV sampling offers a number of advantages over other diagnostic methods: 
Firstly, overall EV levels are usually elevated in disease – a finding that has been proposed as a 
simple measurement tool, but also engendered skepticism over disease-specific value. Thus, a 
‘general stress signal’ view is adopted by many 6,15,46,47. However, repeated evidence has 
emerged of EV enrichment with specific molecular components (RNAs, proteins, and lipids) that 
reflect the status of the parental cell; in many, but not all cases, these biomarkers are enriched in 
the EVs in a disease-specific manner 47-50. These findings have motivated research beyond 
disease correlation into establishment of causality: thus EVs might represent not only robust 
vehicles of disease-specific biomarkers, but therapeutic targets in themselves.  
Secondly, the lipid bilayer of EVs contributes further to diagnostic utility by protecting 
biomacromolecules and stabilizing them from RNases, proteinases, and other enzymatic activity 
present in the biofluids. For example, in bovine milk,	 naturally existing miRNA and mRNA 
which were associated with EVs were shown to be resistant to adverse acidic conditions (treated 
for 1 h in an acidic (pH 1) solution) and RNase treatment while synthetic spiked-in miRNAs 
were prone to degradation under similar conditions 51,52. Several other reports showed that the 
total yield of EV RNA is not significantly changed after treatment with RNase, irrespective of 
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EV origin: cell culture media, serum, or plasma 9,11,12,23. Thus	 EVs are very stable allowing 
storage for an extended period of time, in start contrast to many biomarker assays that require 
processing of fresh biofluids 53.  Furthermore, in a multiplex study on ovarian cancer patients 
which identified eight miRNAs for discrimination of  ovarian cancer from benign ovarian 
disease, miRNA levels were not altered by pre-analytical variables such as collection and storage 
time 14.  Thus, analysis of biomarkers within the EV fraction of biofluids promises a potential 
solution against poor analyte stability and deviation from sample handling standard operating 
procedures (SOP), which are factors well known to confound the outcomes of plenty a clinical 
trial 24,47,54.  
Thirdly, notwithstanding therapeutic relevance and sampling robustness, EV-based analysis 
offers a substantial statistical advantage in reducing biological matrix complexity and thereby 
overall assay noise. This significant improvement facilitates considerably more specific and 
sensitive detection of low abundance biomacromolecules 47,50,55 or analytes with varying levels 
within sub-compartments of a complex biological matrix. A simple analogy can be drawn with 
the value of cell sorting in diagnostic haematology56, as well as in vivo pharmacology 57. This is 
commonly referred to as the “less is more” principle: a smaller, but more defined sample is 
highly enriched for specific biomarkers during the exosomal sorting and isolation process, that 
would otherwise constitute only a very small proportion (less than 0.01% v/v) of an unprocessed 
biofluid sample 58. Thus, several studies reported increased sensitivity for EV-based biomarkers 
compared to whole serum and urine biomarkers 59-61. For instance, miRNA found in EVs isolated 
from sera of patients with colorectal cancers, showed higher sensitivity (90%) compared to 
serum biomarkers CEA and CA19-9 (30.7 and 16% respectively) 59. In several studies, higher 
levels of disease-specific biomarkers were found in the EV-enriched fraction of biofluids 
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compared to the EV-depleted fraction 61,62. For example, a miRNA subset enriched in EVs 
isolated from the serum of prostate cancer patients was hardly detectable in healthy subjects. In 
stark contrast, the most abundant miRNAs in EV depleted sera were recovered from both healthy 
and prostate cancer subjects61. Similarly, in alcoholic hepatitis, serum/plasma miRNA-122 and 
miRNA-155 levels were correlated with liver damage and were predominantly associated with 
the exosome-rich fraction (around 5 times more) compared to the non-exosome fraction 62.  
Consequently, the potential value of EVs has not escaped the attention of the personalized 
medicine community 20,63,64.  However, there remain significant challenges in the 
commercialization of such approaches beyond centralized, specialist laboratories and especially 
in diagnostic kit format. Thus, whilst the US FDA enables regulated (CLIA) laboratories to carry 
out so-called ‘homebrew’ tests, including on fractions of samples such as EVs, marketing of such 
diagnostic tests in kit format requires up to phase III clinical trials and regulatory approval in line 
with the standards for reporting diagnostic accuracy (STARD) 65. In Europe regulations are 
presently less stringent, through the self-certification CE marking scheme, but this is expected to 
align closer with FDA standards within the coming 5-10 years 66. Recent changes to this 
framework comes in the form of the FDA’s de novo regulatory path for diagnostics development. 
This route has been opened to enable new analytical methodologies with no previous golden 
standard, such as whole genome sequencing, to reach the market. However, as evidenced 
through several instances of FDA intervention (e.g. Theranos), sample processing, wherein EV 
enrichment falls, is considered a separate step to analyte measurement technology in the 
diagnostic SOP continuum. Thus, commercialization of  EV enrichment technologies is expected 
to follow the 510k FDA pathway, requiring high levels of clinical rigor and validation ahead of 
diagnostic use marketing. This will most probably be achieved with enrichment device/process 
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alignment with one or more innovative biomarkers, whose commercial value pivots on the SOP, 
stability, statistical, and the ‘less is more’ principles cornerstone to the utility of EVs for 
biomarker recovery. Thus, the predicted EV biomarker workflow is depicted in Figure 3. 
Challenges for Standardization of EV biomarker discovery  
Despite the great interest in the role of EVs in different pathological conditions, there exist 
important limitations at the pre-analytical, isolation, characterization, biological, clinical and post 
analytical levels. Together, these contribute to confound concordance between different studies 
and raise questions with regards to ultimate clinical value. In line with the value of 
standardization in other separation-based diagnostic technologies, establishing an efficient, rapid 
and reproducible isolation method is crucial to analytical reproducibility. In the last few years a 
variety of EV isolation technologies have been developed with each technique providing specific 
advantages and disadvantages to downstream analytics. Consequently, the lack of 
standardization hinders the translational process. Validation studies pivot on the systematic, 
orthogonal transfer of methods from research to development, in a manner that is end user-
friendly and as simplified as possible. Indeed, many of the presently available methods are 
inherently prone to variance or poorly suited to standardization for the diagnostic laboratory 
setting.  
EV isolation methods  
Although EVs have been successfully isolated from different biofluids, including CSF 67, plasma 
68, urine 69, serum 3, saliva 70, amniotic fluid 71, and breast milk 72, the enrichment methods have 
included ultracentrifugation, antibody-coated magnetic beads, microfluidic devices, polymeric 
precipitation technologies, size exclusion, sieving, porous nano-structures, and other new 
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technologies (Table 4). Yet the impact of sample processing on study outcome is nothing new 21 
and extends the paradigms of confounding factors reported for various proteomics and 
transcriptomic methods, even metagenomics and microbiomic studies73. To date, none of these 
reported methods has been shown to offer consistent superiority, whether by diagnostic purpose, 
type of biofluid, EV subclass or clinical setting. Indeed, either one or a combination of these 
methods might be used. Selection of a preferred method is greatly dependent on the goal to be 
achieved as well as preconceptions, assumptions and individual laboratory habits. In general, 
researchers aim for high EV purity and yield, either at the whole population of EVs or a subclass 
(exosomes, microvesicles, apoptotic bodies). The choice, however, is based on concurrent trends 
for the target disease, perhaps specific mechanistic interests in the underlying pathology, but 
principally on grounds of resource intensity (cost effectiveness against process complexity). 
However, preferential aim tradeoffs should be made depending on the circumstances, with 
hypothesis-driven mechanistic considerations at the center of process selection in order to 
maximize effectiveness.  
Ultracentrifugation 
Traditionally, the gold standard and most commonly used protocol for EV isolation/purification 
is differential centrifugation, which involves multiple centrifugation and ultracentrifugation 
steps. As protocols vary between users, this may lead to inconsistencies in the recovery of EVs. 
In general, the centrifugation protocol starts with a low speed centrifugation (300-500 g for 10-
15 min) to pellet cells, followed by a medium speed (10,000 to 20,000 g for 20 min) to eliminate 
larger vesicles and a final 100,000 g ultracentrifugation step for >2 h to pellet EVs. The protocol 
should be optimized based on important factors such as viscosity74 and rotor type (k factor)77. 
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Thus, in conditions that alter sedimentation rate, or diseases that increase the viscosity of  
biofluids such as hyperviscosity IgM syndromes, cryoglobulinaemia, and macroglobulinaemia,  
the dilution of biofluids prior to ultracentrifugation should be considered 24,75. Similarly, the rotor 
k-factor is a commonly ignored parameter that, nonetheless, underpins the rotor efficiency in 
pelleting particles. Briefly, the value of the k-factor is determined by the maximum angular 
velocity (ω) of a centrifuge (in rad/s) and the minimum and maximum radius (r) of the rotor 21,76. 
Consequently, yhe k-factor can influence the purity and yield of exosomes in the 
ultracentifugation steps and can be utilized to predict the time required for achieving the desired 
sedimentation profile. 
Last but not least, the substantial risk of co-precipitation viruses and protein aggregates should 
be considered where such particles are within the EV size range assayed 21. Often this is ignored 
in some protocols, where the first and second centrifugation steps  are replaced by faster, higher 
purity microfiltration techniques 78. To compensate and minimise such carry-over issues an extra 
purification step can be added after the last centrifugation step, such as sucrose gradient or 
immunomagnetic isolation 21,23.   
Size exclusion techniques 
Size exclusion techniques, including ultrafiltration and chromatography, are a rapid and 
inexpensive alternative solution79,80. Although these methods can accommodate a large volume 
of biofluids, they are unable to concentrate EVs, selectively isolate subpopulations and, in the 
case of ultrafiltration, may cause deformation of  large vesicles 24. However, nanomembrane 
ultrafiltration concentrators such as the Millipore Centricon™ and Amicon® Ultra-15 
Centrifugal Filter Devices can be used to simultaneously concentrate and filter the samples 9.  
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Immune affinity isolation 
Immune isolation can increase EV purity and enable selective capture of specific subpopulations 
based on one or more surface markers. In this approach, antibodies against defined surface 
protein markers are used conjugated/coated on beads. The captured EVs are then typically 
separated using magnetic-bead principles 21. The approach is versatile method and compatible 
with downstream analysis including western blotting, flow cytometry, electron microscopy and 
transcriptomics23. Beyond antibodies, other affinity-based methods include synthetic peptides 
such as venceremin (Vn) that exhibit specific affinity for canonical heat shock proteins81, as well 
as target-specific, synthetic, single-stranded oligonucleotides (aptamers)82.  
Polymeric precipitation 
Some newly introduced isolation techniques such as the ExoQuick™ (System Biosciences), 
Exosome Isolation Kit (Life Technologies) and ExoSpin Exosome Purification Kit (Cell 
Guidance Systems) can facilitate sedimentation of EVs from solution during low speed 
centrifugation (10,000–20,000 g) by promoting the precipitation of vesicles with polyethylene 
glycol or other polymers. Although these kits are faster and more efficient than 
ultracentrifugation, they also precipitate protein aggregates and lipoproteins. Interestingly, it 
has been demonstrated that a combination of polymeric precipitation methods, followed by 
immune affinity isolation against e.g. the exosomal marker CD63 can lead to a high yield of 
pure exosome subpopulations 9. Given the success of combinatorial solutions, and the drive for 
SOP simplification, several new material engineering-based technologies have recently been 
introduced. However, clinical and comparative studies on their reproducibility and clinical 
efficiencies are limited.  
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Comparative methodology studies   
The methods outlined above present a variety of physicochemical and biochemical means 
through which EV characterization can be approached. These have the potential to impact 
significantly on the constituents of the resulting processed sample matrix, thereby complicating 
the elucidation of the functional role of EVs, biomarker discovery efforts and targeted analytical 
assay development. Despite worldwide interest in this research area, only a limited number of 
comparative studies have been published in the literature to date.  
Thus, a recent study investigating comparatively the expression profile of 375 miRNAs in EVs 
isolated from the sera of healthy individuals, either by ultracentrifugation or by polymer 
precipitation methods, reported that differences in the observed miRNA profile of EVs can be 
affected by the isolation method 83. Elsewhere, 100 nm-liposomes fabricated with 1,2-dioleoyl-
sn-glycero-3-phosphocholine (DOPC) and cholesterol were used as a model system to assess 
the effect of isolation protocols on EV recovery and size distribution84. Among the four 
different purification protocols evaluated, ExoSpin, Invitrogen kits, PureExo, and 
ultracentrifugation, the first two achieved up to 2 orders of magnitude higher EV yields. 
However, the authors did not characterize the recovered EVs based on surface markers or 
physicochemical methods such as dynamic light scattering and tunable resistive pulse sensing 
84. Van Deun et al., evaluated the role of different isolation protocols in downstream ‘omics 
approaches for biomarker discovery. Density gradient centrifugation (Optiprep) yielded purer 
CD-63 positive EV fractions with less contaminating proteins such as Argonaute-2 (Ago2) 
complexes 85. Amongst other functions, Ago2 is a member of the RNA-induced silencing (RISC) 
complex and is considered an extracellular RNA-binding protein which is associated with the 
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non-EV related fraction86. This preparation revealed a unique mRNA profile enriched for 
translation machinery and ribosomal proteins 85. In a study conducted by Alvarez et al., 
ultracentrifugation (traditional protocol, in combination with filtration or sucrose cushion) was 
compared to two other precipitation-based methods (ExoQuick-TC, System BioSciences) 87. The 
authors modified the ExoQuick protocol and increased final centrifugation speed to 10,000 g, 
instead of the 1,500 g recommended by the manufacturer. Maximal EV, miRNA, and mRNA 
yield was obtained using the modified exosome precipitation protocol and RNA quality was 
suitable for downstream profiling. Similarly, Bukong et al., compared ultracentrifugation to the 
ExoQuick precipitation kit ahead of immune affinity isolation against CD63 23. Although 
ExoQuick outperformed ultracentrifugation in terms of EV recovery, both methods resulted in 
very high purity, verified by the abundance of EVs and lack of protein aggregates in transmission 
electron microscopy images. Moreover, western blotting showed high yield of exosomal marker, 
CD63, after isolation with both methods.  Such a combined precipitation and immune affinity 
protocol was found to be well-suited for use in the clinic in terms of simplicity, speed and sample 
throughput.  
Notwithstanding the impact of EV isolation methodology, protein or RNA isolation methods 
may also impact upon the outcome of downstream analytics. Thus, EV RNA patterns were 
reported to vary in size and composition after isolation using different methods 88. Mouse MC/9 
cells were cultured and EVs were isolated by ultracentrifugation. RNA was isolated from EVs 
using seven commercially available RNA isolation kits. Generally, column-based methods were 
reported to outperform phenol-only or combined phenol and column approaches in terms of 
RNA yield and the highest yield was achieved by miRCURYTM RNA with the mean of 21.8µg 
versus 6.1µg for Trizol. These studies clearly demonstrate a growing, and largely unmet need for 
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standardization and validation in EV sample preparation. Although precipitation methods are 
amenable to rapid, highly scalable, and effective EV isolation, clinical protocols require careful 
consideration of the research question. Furthermore, assay migration between methods should be 
supported by well-controlled studies leading to verification of successful implementation in the 
clinic prior to use. Researchers and clinicians should pay special consideration to the type of 
target biofluid as well as the type of biomarker, as different methodologies might be better suited 
for alternative matrices and analytes to those commonly used by a research group 89,90. Readers 
are thus advised to implement appropriate comparative and confirmatory protocols as part of 
their pilot work in preparation of large scale studies. 
Clinical, biological, and analytical challenges of EVs as biomarkers 
The methodological variance in the EV biomarker research continuum is further augmented 
through additional clinical, biological, and analytical challenges ( 
Table	  5). In the absence of proper study design and normative controls it is impossible to 
partition biological variation from technical variation. It has thus been showed that demographic 
variables such as age, gender, and ethnicity can affect EV signatures 91-93; yet control groups 
over age, gender, and ethnicity common to other clinical research is largely lacking in EV-
targeted studies 24,92. Alternatively, pooled healthy subject samples can be used as a control 94. 
Elsewhere, repeated sampling of the same patient in the course of disease has been used to 
determine the  variability of a specific EV-associated biomarker 24. Other factors such as 
physical activity and diet have also been shown to affect EV release patterns and cargo; these are 
additional parameters that should be considered in study design or be adjusted for 95,96. 
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Furthermore, as with other biomarker technologies, protocol standardization and consistency 
throughout sample acquisition, storage, and processing should be aimed for.  
A major challenge in EV-based diagnostics is the complexity of EV secretion mechanisms in 
different pathological conditions which is intertwined with the activation of a complex network 
of diverse, cross-talking molecular pathways with adaptive feedback loops. The biomarker field 
has shown repeatedly that patient stratification and better disease discrimination can be achieved 
through the use of more than one single marker of disease. Indeed, there are examples, including 
in the field of EV research, where combined analysis of different classes of analytes can 
substantially improve sensitivity and specificity 61.  Thus, Madhavan et al. reported an increase 
of pancreatic cancer-initiating cell protein markers including CD44v6, Tspan8, EpCAM, MET 
and CD104 as well as increases in the levels of miRNA-1246, miRNA-4644, miRNA-3976, and 
miRNA-4306 in the serum-exosomes of pancreatic cancer patients compared to patients with 
chronic pancreatitis, benign pancreatic tumor and healthy controls 61. Crucially, combined 
measurement of proteins and exosomal miRNA in discriminating pancreatic cancer from other 
type of pancreatic diseases and health increased sensitivity up to 1.00 (CI:0.95-1.00) compared to 
protein analysis (0.96, CI: 0.88-0.99) or miRNA analysis (0.81, CI:0.71-0.89). The specificity for 
the combined approach was reported to be 0.80 (CI:0.67-0.90). These results make a strong case 
for signature biomarkers to transcend analyte classes. 
Indeed, such an approach might broaden the knowledge and shed new light into processes 
through detection of previously overlooked factors and/or systems associated with systemic 
disease. For example, in a study of EV biomarkers in alcoholic hepatitis using chronic alcohol-
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fed mice, in addition to  miRNAs specific to liver (miRNA-192 and miRNA-122), the organ 
principally affected by ethanol intake, miRNAs specific to other organs including the heart were 
also detected 3. It is presently unclear whether alcohol is causal or consequential to the observed 
impact on the heart, however such outcomes can help initiate illuminating follow up studies. 
Notably, where causality between biomarker and condition is not been established, so-called 
‘association’ biomarkers can be considered confounders, might have limited validity in disease 
diagnosis and, crucially, lead to misinterpretation of data pertinent to the success of therapeutic 
interventions 97. Yet evidence is emerging that the biomaterials directed into EVs under 
conditions such as alcoholic stress are highly regulated and do not always mirror fully the 
functional status of the originating cell. Thus, Saha et al. 98, reported that both miRNA-146 and 
miRNA-27a are significantly elevated in monocytes after ethanol exposure. However, only 
levels miRNA-27a appeared to be directed to EVs. Thus the interpretation of specific EV 
signatures should be anchored across the domains of correlational and causal biomarkers. 
Furthermore, variability across studies may assist in identifying associational biomarkers, which 
are more prone to bias and confounders.  
In addition, difference in EV subtypes 99, secretion mechanisms, and cargo changes in various 
stages of disease 100 must be taken into consideration. For example, Ji et al. 99, showed that a 
colon cancer carcinoma cell line (LIM1863) released two distinct subtypes of exosomes, 
enriched in apical surface sorting proteins or basolateral surface sorting protein. Deep 
sequencing and proteomic analysis of the two subpopulations showed distinct miRNA and 
proteome profiles 99,101. Thus, in vivo and patient observations need to be supported by parallel 
evaluations in cell lines, tissue culture and primary cell research, with particular attention to 
mechanistic detail in recapitulating the organism milieu. These efforts will help elucidate the role 
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of an EV release event in disease and inform the likelihood of recovery from a given biological 
matrix. 
Research ‘omics and the post-‘omic clinical era: the example of RNA and EVs. 
Accurate measurement of biomarkers, be they EV preparations or otherwise, pivots on analytical 
platform limit of detection, dynamic range, and the capacity of current technologies to 
comprehensively identify, interpret and manage the resulting data. Moreover, there is a critical 
need for transparency and reproducibility in the pipeline of biomarker discovery, including 
patient recruitment, data gathering, and processing – the so called open science model. The 
approach presents a unique proposition in fundamentally altering our approach to unlocking 
mechanisms of disease and disrupting patient care.		
New advances in high-throughput technologies have ushered in the era of ‘omics science- the 
simultaneous agnostic survey of tens to millions of biomarkers including, transcriptomics, 
proteomics, lipidomics and metabolomics 102,103.  Although ‘omic technologies have been 
utilized in EV studies, the amount of literature is limited. Yet disease development is a complex 
process; inherited susceptibility and different environmental exposures can modulate disease risk 
and progression in an individual over time. These introduce dynamic interactions in the evolution 
of individual molecular mechanisms of disease initiation and progression. For example, the 
cancer genesis process is presently understood to be characterized by stochastic accumulation of 
mutations and dynamic evolution of clones. Thus, whole genome instability measurements and 
genome-based cell population heterogeneity have been linked to stages of cancer development 
104,105. Currently, most cancer biomarkers do not reflect the evolutionary dynamic of cancer 
progression but rather focus on specific deregulated pathways. Development of biomarkers for 
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cancer risk management should consider these stochastic and dynamic properties over time in 
neoplastic evolution.	This approach is fundamentally different from the commonly used three-
stage disease category of normal, disease without symptoms, and disease with symptoms model 
for biomarker screening. In fact, using stochastic modeling might provide a framework for 
guiding future biomarker research to enable more accurate patient stratification into various risk 
groups, each with a different cancer risk distribution, thereby facilitating adaptive cancer risk 
strategies. This method can enable the optimization of available resources and intervention 
timing based on particular biomarker sensitivity and specificity in predicting disease progression 
and prognosis among various risk groups that dynamically evolve over time. Of course the 
challenge that remains is arriving at study numbers adequately powered to achieve statistically 
interpretable outcomes. 
Yet such an approach is not without precedent, albeit with considerably reduced levels of 
complexity: staging of cancers on account of histology has increased the granularity of our 
understanding and altered our approach to treatment. Progressively, this is further enriched as 
more and more clinically validated interventions and their associated biomarker solutions come 
online. Expanding on this principle by integrating clinical findings with research ‘omics towards 
the construction of large scale Bayesian models (where the probability of given states is 
estimated based on a given set of starting points) promises a ‘live’ treatment and response 
scenario. Presently, this is done empirically. However, by continuously repositioning the 
collective understanding of such a diverse disease against the equally disparate patient 
background and treatment outcomes might indeed present a more realistic and accurate approach 
for contextual biomarker validation, understanding of disease mechanisms, 55,106 and 
personalized intervention to the benefit of all stakeholders: patients, clinicians and researchers. 
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To achieve this, it is necessary to work towards etymological and methodological concordance, 
or at the very least, provide adequate bridging principles, that will enable the necessary level of 
participation, i.e. on a global, continuous scale. However, there are few incentives to academics, 
institutions and the industry to share. 
For example, transcriptomics is the study of the complete set of transcripts in a particular cell, 
tissue, sample or organism for a given physiological or pathological condition 107. The 
transcriptome includes protein-coding messenger RNA (mRNA) and non-coding RNA (ncRNA: 
miRNA, long non-coding RNA (lnc-RNA), ribosomal RNA (rRNA), transfer RNA (tRNA), and 
other ncRNAs) 108-110. Since the transcriptome is a dynamic entity underpinning homeostasis, 
frequently altered during disease and treatment, transcriptome analysis has attracted a lot of 
attention in the study of EV function. This is challenged by the low abundance of EVs in 
biofluids. However, at least three approaches allow medium/high throughput detection of 
transcriptomic biomarkers including amplification based methods, hybridization-based 
microarrays, and Next Generation Sequencing (NGS). Amplification-based assays enable 
measurement of panels of both miRNA and mRNA and expand upon the concept of quantitative 
reverse transcription PCR (qRT-PCR). Popular examples include the SAbiosceinces PCR array, 
TaqMan OpenArray, TaqMan Gene Expression Assays, TaqMan TLDA microfluidic cards by 
Applied Biosystems, miScript miRNA PCR Array by Qiagen and miRCURY LNA qPCR by 
Exiqon. All these platforms offer high sensitivity and can precisely detect changes in tens to 
hundreds of individual nucleic acid levels whose existence is known a priori and for whom 
assays can be designed 111. Advantages include a multi-log (5-9) linear dynamic range, resistance 
to purification protocol changes and organic contaminations. However, these technologies are 
mostly limited to medium throughput and annotated genes supporting hypothesis-derived 
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discovery 112. Correlation and reproducibility of each platform in the context of EV-based 
biomarkers remains to be determined. It is, unfortunately, generally assumed that differences 
would reflect the minutiae of assay engineering differences with respect to target annotation and 
mechanism of amplification. 
Hybridization-based assays (microarrays) are powerful tools for high-throughput evaluation of 
thousands of transcripts (hundreds to tens of thousands) in one assay and have been used in EV-
based studies. There are two types of microarrays: short-oligomer microarrays (e.g. Agilent, 
Affymetrix Genechips, Nanostring), and long probe microarrays which include cDNA 
microarrays that may probe sequences up to a few hundred bases in length 113. Microarrays are 
also limited to known target sequences, feature considerably reduced cost per analyte, but suffer 
less specificity, reduced dynamic range, and poor reproducibility 111. Indeed, poor specificity has 
been demonstrated to drive discrepancies in gene-expression profiles between different probes 
targeting the same region of a given transcript 113,114, whereas operator and day-to-day variability 
are common problems in microarray data analysis 114. For this reason, many a microarray-based 
study’s outcomes are validated by qRT-PCR methods with little, if any, effort to detail and 
compensate for methodological bias or compatibility, but rather on the assumption that statistical 
significance across two analytical approaches is adequate. 
Next generation sequencing combines the advantages of amplification-based ‘omics with the 
throughput of microarrays to yield global sequence data agnostically 115,116 that can inform 
variability over single nucleotide polymorphisms (SNP) 117, alternative RNA splicing 118, copy 
number variations (CNV) 119, and differential expression (RNA-seq) 116 in a digital fashion. At 
first glance this is superior to either qRT-PCR or microarray approaches. Thus, the sequences of 
all transcripts in a sample are reverse transcribed into cDNA, prepared into a sequencing library, 
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read, bioinformatically mapped against a reference genome and individually quantified at a cost 
per analyte (base) orders of magnitude lower than microarrays. At ~US$400 several tens of 
terabytes of sequence data can be generated with billions of datapoints per sample. The resulting 
analytical feat requires expert computational know how and infrastructure to undertake. 
However, the technology  is sensitive to the relative abundance of individual transcripts in a 
sample, amplification method artifacts, chemistry-related bias and detection technique-mediated 
error – notwithstanding computational limitations (aligner bias, reference genome bias). Thus, 
low frequency transcripts require ‘deeper’ (i.e. more) sequencing at a risk of artifact detection 
and mis-identification. Furthermore, as sequence ligation (adapters) is common in many 
sequencing library preparation methods, ligase sequence preference artifacts have been described 
to influence transcript frequency detection120. Moreover, nucleic acid contaminants arising from 
the biological origin of the processing enzymes can also contribute to confounding datasets 
121,122. Presently, each of the four most popular, commercially available RNA sequencing 
platforms has its own significant advantages and disadvantages. Briefly, Illumina NGS is an 
evolution of microarray technology and the most widely adopted platform, as it is less prone to 
error on account of homopolymer regions (e.g. adenosine multimers An, where n > 6). However, 
as with microarrays, it is based on imaging and base-by-base template extension, which makes it 
slow, costly and high maintenance. Moreover, it is subject to frequent chemistry and 
instrumentation updates that affect data quality and compatibility. On the other hand, it is the 
only approach that has been used to date to generate RNA-Seq data directly on histology sections 
by applying clonal template amplification on tissue sections 123. The Ion Torrent technology is 
based on semiconductor microchip pH sensors of nucleoside addition. This detection 
methodology dramatically accelerates the data yield rates and enables robust hand-held NGS at 
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the bedside (DNA Electronics), but has a lower throughput than Illumina and is hampered by 
homopolymer errors and insertion/deletion artifacts. Both Illumina and Ion Torrent have <400 bp 
sequence limits and require sample fragmentation and clonal amplification; this causes problems 
in the analysis of repetitive regions and introduces further risk of error. Pacific Biosciences on 
the other hand uses optical, real time, single molecule sequencing which permits reads of up to 
hundreds of thousands of bases in length, but is a very slow, error prone, high cost and large 
footprint platform. Similarly, Oxford Nanopore also offers real time single molecule sequencing, 
this time on a sequencer the size of a USB stick that uses conductivity across a synthetic lipid 
bilayer to analyse transcript sequences as these transverse an engineered protein pore. It is 
considerably cheaper and faster than Pacific Biosciences, but it is a temperature- and kinetic 
energy-sensitive, considerably lower throughput instrument with a much higher error rate. In the 
next few years more robust, solid-state nanopore technologies based on graphene and other 
materials are expected to replace biological nanopores. Thus, where Illumina and Ion Torrent are 
good for counting non-repetitive sequences, Pacific Biosciences and Oxford Nanopore are better 
at developing complex repetitive sequence scaffolds and for RNA-SEQ splice variant 
enumeration. Few studies aim to bring together the advantages offered by each platform on 
answering clearly specific research questions. Rather the community is absorbed by the 
commercial marketing efforts and accessing answers with the least possible resistance, often 
with the least useful value. To the best of our knowledge these methodologies have not been 
evaluated yet in single EV sequencing and, by extension, to comparative sequencing of 
individual EVs. Notably, although for many years the cost of these technologies drove analysis 
to focus on single replicates, presently, independent biological and technical replicates are 
considered necessary 116. 
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In their effort to understand the role of EV in disease, the reader is directed to the several 
databases that have been introduced to publicly source datasets of studies investigating mRNA, 
miRNA, but also proteins in biofluids including Exocarta 124, ExcellmiRDB 124 and miRandola 
125. However, most of the studies in these databases utilized targeted as opposed to genome- wide
association studies 126. Since the targeted-approach is based on an a priori knowledge of gene 
function in disease pathogenesis, it is highly hypothesis-dependent and may overlook other 
active network components, negative/positive feedback loop elements and indeed RNA 
editing/splicing changes 127,128. Moreover, false positive / negative error rates, in many cases not 
taken account of, confound data replication in follow-up studies 128. The reader is therefore 
advised to approach the interpretation and extrapolation of these results with caution.  
Eirin et al. 129, performed transcriptome profiling on EVs derived from mesenchymal stem cells 
of adipose origin. These contained mRNA for transcription factors (e.g. NRIP1, POU3F1) and 
genes involved in angiogenesis and adipogenesis, genes involved in TGFβ signaling pathway, 
and selected miRNAs. Gene ontology analysis revealed that these miRNAs might target genes 
and transcription factors that contribute to several cellular pathways, including angiogenesis, 
apoptosis, cellular transport, and proteolysis. Interestingly, this enrichment was selective; 
cytoskeleton and mitochondrial gene families were excluded from these EVs 129. Contemporary 
to the explosion of interest in EVs, miRNAs became established as nodal regulators of gene 
networks: data indicated specific miRNA could drive cell phenotype. Thus many EV 
transcriptomic surveys focused on this class of RNA analytes exclusively to reveal that up to 
76% of all mappable reads generated by RNA-Seq on EVs were indeed miRNA transcripts11. As 
was concluded from target gene enrichment analysis and functional experiments, these miRNAs 
might play important functions in protein phosphorylation, RNA splicing, and the modulation of 
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immune functions 3,11,47. However, miRNAs are present in biofluids in three forms: cell-derived 
EVs, high-density lipoprotein particles, and Ago2 protein complexes 130,131. The sorting of 
miRNA to the EVs is indeed specific and selective3 and may include, amongst others, the 
miRNA motif and sumoylation of heterogeneous nuclear ribonucleoproteins (hnRNPs) C 
pathway 132, the neural sphingomyelinase 2 (nSMase2)-associated pathway 133, and the RNA 
induced silencing complex (RISC)-related pathway 134. On the other hand, the mechanism of 
extra-vesicular miRNA release is poorly understood. The reader is thus advised to consider the 
impact of sample processing methodology on the outcomes reported between studies. 
Nevertheless, there is strong biomarker and clinical diagnostic potential in EV miRNAs 47,135-142. 
Table 6 demonstrates a summary of the use of EV-associated miRNAs in clinical settings for 
biomarker discovery and disease prognosis. Validation in large independent cohort studies, 
however, can sometimes be contradictory. For instance, differential regulation of a total of 143 
miRNAs in plasma or serum in 32 breast cancer biomarker publications is demonstrated in which 
100 deregulated miRNAs were reported in only 1 publication 54. 
One possible explanation for these discrepancies suggests that miRNA expression changes in 
biofluids might occur earlier than conventional biomarkers, but this is often overlooked or not 
evaluated at all ahead of designing clinical validation studies. For example, in a cardiovascular 
ischemic events, circulating miRNAs (miR-1, -133a, and -133b) achieved their peak around 3h 
before the commonly used troponin I (TnI) peak 143. Similarly, markers of inflammation and 
damage in cardiovascular disease, such as C-reactive protein and cytokines are observed in a 
later stage than miRNA deregulation Complexity also arises from the apparently non-specific 
elevation of certain circulating miRNAs such as miRNA-21 135,145, which confound identification 
of disease-specific miRNA profiles. Integrating miRNA panel data in systems biology as 
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opposed to focusing on single miRNAs can, however, help facilitate patient classification. 
Alternatively, measuring commonly dysregulated miRNAs might offer value not in disease 
screening but in disease monitoring or prognosis studies 54. For instance, the levels of three non-
specific cancer-related miRNAs, miRNA-21, -221, and -141 in blood plasma of prostate cancer 
(PCa) patients have been demonstrated to be useful for predicting metastasis within patient 
subgroups 146. Another challenge involves the data normalization approach used. Thus, in RNA 
studies, including miRNA, target levels are typically expressed relevant to at least one, but more 
commonly more than three different RNA targets not influenced by the disease/treatment, as 
determined through comprehensive profiling of normative samples for each biofluid. Indeed, 
many published studies provide selections of normalizing targets without adequate supporting 
evidence, perhaps beyond habitual use. These variables, in addition to sample processing, should 
be standardized ahead of attempting to establish clinical utility in independent cohorts 
147. Alternatively, a unified means of cross-study normalization, perhaps through automated
selection of common normalization features (e.g. common normalizing gene subsets) could be 
adopted. Interestingly, since the number of EVs and their associated miRNAs is increased in 
various diseases, it has been proposed that using the same amount of starting material (µl of 
biofluid) might be a more suitable and adequate approach as compared to standardizing the 
amount of EV-associated miRNA extracts 24,47. This is not dissimilar to the single analyte 
approach common to viraemia analytics used in research. However, the approach is superseded 
by the use of endogenous normalization and/or spike in controls. Thus, in the absence of a 
globally harmonized biomarker reporting and data integration system, it is our view that more 
meticulous studies, with better thought out controls, based on much larger patient cohorts along 
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with side-by-side comparisons with clinical parameters and conventional biomarkers are required 
for evaluating the utility of EV-associated miRNAs in the clinic. 
EVs and DNA biomarkers 
Genomic DNA  biomarkers report genome-level changes using a variety of methods, including 
genome sequencing, qPCR and digital PCR 148 to accurately report SNPs, CNVs, genomic 
rearrangements and rare genetic sequences that functionally underpin the pathophysiology of  
disease 149. This approach is most frequently used in oncology. However, tumor analytics have 
long been known to suffer operator and sampling biases. Thus, tumor heterogeneity is not fully 
represented within a given biopsy, irrespective of the analytical platform used. Yet genetic 
changes in tumor tissues are also mirrored in biofluids and EVs 20,150. Importantly, these 
extracellular DNA sources may capture a snap shot of the disease state to be used for diagnosis, 
disease monitoring, and therapeutic stratifications – particularly in ‘deep sampling’ (i.e. NGS) or 
highly sensitive (e.g qPCR) methods 47, without the need for invasive biopsy. Presently NGS is 
restricted to highly specialized, centralised clinical settings worldwide with significant research 
activity and are not suited to disease screening in health care settings. NGS targeted to specific 
sequences  relying on a priori data/hypothesis is more cost-effective, allows for deeper sampling 
of commonly mutated genes, can simplify NGS analytics and therefore is the leading approach 
pursued for diagnostic NGS dissemination 125. Crucially, targeted NGS has comparable 
sensitivity and specificity for detection of disease specific mutations to Sanger sequencing, but 
benefits from significantly higher levels of data yield, can report unexpected mutations in key 
genes and inform digitally mutation abundance 125,151.  
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At first glance, the presence of DNA in EVs would indicate their apoptotic/necrotic nature (DNA 
fragments) as opposed to their enrichment in actively produced vesicles such as exosomes. As a 
result, the utility of EV-associated DNA has so far been less explored. Nonetheless, double 
strand DNA (dsDNA), mitochondrial DNA (mtDNA), single strand DNA, and oncogenic 
amplifications have reportedly been detected in EVs 103,152-156. Double strand DNA was isolated 
from EVs originateing from different human cancer cell lines, including chronic myeloid 
leukemia and colorectal carcinoma 153. Genomic DNA reflecting the mutational status of parental 
tumor cells was found in EVs 153,157,158. DNA containing amplification of the oncogenic c-Myc 
was isolated from circulating EVs in glioblastoma patients 155.  In another study, >10kb 
fragments of double stranded genomic DNA were detected in exosomes originating from 
pancreatic cancer cells and sera of patients with pancreatic ductal adenocarcinoma. Mutations in 
KRAS and p53 were also detectable in the EVs isolated from patients’ sera 159. Additionally, 
whole genome sequencing demonstrated that serum exosomes from patients with pancreatic 
cancer contain genomic DNA originating from all 23 human chromosomes 159. These findings 
suggest that EVs might hold value as translational biomarkers in identifying parental cell 
mutations. Elsewhere, mtDNA has been isolated from glioblastoma and astrocyte-derived EVs 
but their functionality remains unclear 154. Moreover, Whole-exome sequencing and genome-
wide copy number profiles of EVs isolated from plasma and pleural fluid showed robust 
representation of the tumor DNA within the shed EV compartment in patients with 
pancreaticobiliary cancers 150. 
Crucially, actionable DNA mutations such as NOTCH1 (cell survival and apoptosis) and 
BRCA2 (DNA repair) as well as fusion genes with well-described causal roles in oncogenesis 
(e.g. APBA and STXBP1, ACOT1 and LMCD1) were found in circulating EVs 150. Interestingly, 
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different subpopulations of EVs (i.e. exosomes, microvesicles) have also been reported to carry 
different amounts of gDNA 158. For instance the relative ratio of PTEN, TP53 and MLH1 gDNA 
fragments was reported to vary by EV subpopulation as quantified by qPCR, using the GAPDH 
housekeeping gene as a reference 158. It is unclear however if GAPDH is indeed an EV 
‘housekeeper’, or a normalizer selected habitually from RNA studies. Nevertheless, collectively, 
these studies suggest that the DNA content in circulating EVs might not reflect parent cell 
viability, but perhaps active shedding of genomic fragments as they become compromised 
through genomic instability, and lend further support to their clinical evaluation as minimally 
invasive liquid biopsies. However, more high-throughput studies are needed to establish the 
functional significance of EV- associated genetic material in various disease 156.  
Systems medicine approach and EV-associated biomarkers 
To date, the amount of validated biomarkers is considerably disproportionate to biomarker 
discovery investment  160-162. A large fraction of these funds were dedicated to studies on specific 
biomarkers of interest at selected time-points, as opposed to the agnostic discovery followed by 
kinetics description and hypothesis-driven validation model of biomarker development and 
clinical translation. Emerging during the ‘omics era, EV biomarker studies have fared better and 
have benefited from inherent advantages that enhance their utility in disease detection, 
stratification, prognosis and monitoring in the context of personalized medicine 47,140,163-165. 
Furthermore, multi-analyte biomarker studies have enabled integrative analytical approaches to 
data mining 166, which cannot be implemented in single biomarker studies in accounting for 
complex phenotypes and stochastic alterations. From a biological stand point, single molecule 
variability within and across diseased and healthy individuals is subject to inherent biological 
noise not statistically accounted for in focused studies 167. The conceptual framework of 
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integrating ‘omics data, systems biology approaches, and personalized medicine in EV 
biomarker studies is depicted in Figure 4. Thus, multiple studies can be used to identify 
biomarker sets (signatures) instead of single biomolecules, in a temporally robust manner not 
subject to irrelevant changes such as circadian rhythms (Table 5). Integration of affected 
biomarkers in systems biology models can inform the affected disease pathways, leading to the 
identification of causal biomarkers instead of simply correlational outputs and, by extension, 
point the way to nodal points of pharmacological intervention in a quantitative fashion 168. Most 
importantly, the system approach takes into account the interrelating biological roles of pathway 
components, making it less sensitive to biological heterogeneity.  
Eventually, the concepts of stratified medicine and systems biology are expected to drive 
personalized medicine into producing truly tailored treatments based on underlying disease 
mechanisms relevant to individual patients. However, to achieve this, a range of novel disease-
specific biomarkers with relation to specific dysregulated pathways needs to be identified. In 
addition, a reference profile for cell-specific and tissue specific EVs molecular signatures is 
needed. Qualitative and quantitative modeling of EV molecular signatures can pave the way for 
EV-based monitoring and prospective diagnosis. 
Conclusions 
EVs continue to gain increasing attention as major players of cell communication with strong 
potential as causal, clinical biomarkers. Translational success will pivot on appropriate quality 
assurance and method validation across the continuum of discovery to clinical implementation. 
As stable reservoirs of different biomolecules, EVs suffer fewer challenges than other analyte 
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matrices, and have the potential to serve as high value liquid biopsies in clinical diagnostics.  
Profiling of EVs can accommodate tumor heterogeneity and can be relatively to completely non-
invasive, based on the biofluid selected. The substantial progress in the isolation, 
characterization, and elucidation of the biogenesis and functional roles of EVs in various 
physiological and pathological states is balanced by the major challenges and urgent need for 
methodological harmonization and better study structure. To translate EV utility from discovery 
to the clinical setting these challenges must be met at the pre-analytical, analytical and post-
analytical phases. In this context, the adoption of systems biology approaches is likely to help 
resolve the analytical challenge of ‘omic datasets, enabling focus on causal biomarkers and the 
transition of EV-based diagnostics to the exciting opportunity of truly personalized medicine. 
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Table 1- Extracellular vesicles (EVs) isolated from different cell types 
Cell type Class Tissue origin EV type Cargo of 
EVs 
Biological 
function 
Reference 
B cells Primary Haematopoietic Exosomes B220 
(CD45R), 
BCR 
complex, 
CD9 and 
CD81 
tetraspanin 
MHC-I and 
MHC-II 
Interaction 
with 
extracellular 
matrix 
169,170
Huh 7.5 
cells 
Immortalized Hepatocarcinoma 
cell line 
Exosomes miRNA-122 Sensitize 
monocytes to 
LPS and 
ethanol effect 
and induce 
pro 
inflammatory 
phenotypes 
in monocytes  
3
THP1 cells Immortalized Human acute 
monocytic 
leukemia 
EVs miRNA-27a miRNA-27a 
cargo in 
monocyte-
derived EVs 
can polarize 
monocytes 
into M2 
macrophages. 
98
Human T 
cell blasts 
Primary Haematopoietic Microvesicles bioactive Fas 
ligand and 
APO2 ligand 
Promoting 
activation 
induced cell 
death 
171,172
TS/A cell 
line 
Immortalized Mammary 
adenocarcinoma 
Exosomes PGE2, TGF-β Suppress 
immune 
responses, 
modifying 
myeloid 
precursors 
toward a 
more 
tolerogenic 
phenotype 
173
MML-1
cells
Immortalized Melanoma EVs miR-214-3p, 
hsa-miR-
199a-3p and 
hsa-miR-155-
5p 
Melanoma 
progression 
174
Renal 
cancer 
stem cells 
Immortalized Human Renal 
Cancer 
Microvesicles proangiogenic 
mRNAs and 
microRNAs 
Stimulate 
angiogenesis, 
formation of 
lung pre-
metastatic 
niche 
5
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Table 2- Disease-related EVs isolated from different human biofluids. 
Type of biofluids Disease Type of EVs Molecular Cargo Changes in 
number of 
EVs in the 
disease state 
Reference 
Serum 
Alcoholic 
hepatitis 
Exosomes miRNA-122 Increased 3 
Glioblastoma Macrovesicles EGFRIII fusion Increased 152
Plasma 
Melanoma Exosomes High protein 
content including 
Met oncoprotein, 
CD44, Hsp70 
No change 175
Nasopharyngeal 
carcinoma  
Exosomes EBV BART viral 
miRNA 
Unknown 176
Hepatitis C Exosomes Hepatitis C virus, 
miRNA-122 
Increased 23 
Milk 
Staphylococcus 
aureus infection 
Exosomes bta-miRNA-142-
5p, miRNA-223 
Unknown 177
Cerebrospinal 
fluid (CSF) 
Alzheimer's 
disease 
Exosomes miRNA-9, 
miRNA-125b, 
miRNA-146a, 
miRNA-155 
Unknown 178
Glioblastoma Macrovesicles CD144, CD4, 
CD45 
Increased 179
Saliva 
Healthy donors Exosomes Different 
miRNAs 
Not applicable 180
Pleural effusion 
Pancreaticobiliary 
cancers 
Exosomes Genomic DNA 
and transcriptome 
reflecting copy 
number profiles, 
point mutations, 
gene fusions and 
mutational 
signatures 
Unknown 150
Urine 
Incipient Diabetic 
Nephropathy 
Exosomes miRNA-145, 
miRNA-155, 
miRNA-130a 
No change 181
Amniotic fluid 
Mid-trimester of 
healthy pregnant 
women 
Exosomes Tubulin, Hsp72 
Hsc73 
Not applicable 71
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Table 3: Role of extracellular vesicles in pathogenesis of different diseases 
Disease Type of vesicles Reference 
Infectious disease 
Parasitic trematodes/nematodes: immunomodulation Exosomes 182
Spongiform encephalopathies: spread of transmissible prions via the blood Exosomes 183
HIV: miRNAs transport involved in HIV-associated neuronal dysfunction, 
trans-infection of CD4+ T-cells 
Exosomes 184,185 
HCV: shuttling virus between hepatocytes, transfer of viral replication 
components  
Exosomes 23, 186
Epstein–Barr virus: viral biogenesis and egress, exosome-dependent immune 
suppression in EBV-associated lymphomas 
Exosomes 187, 188
Cancer 
Promote angiogenesis, thrombosis, and tumor cell proliferation Exosomes, Microvesicles 189-192
Promote a pro-tumor environment to harbor metastatic niches and formation of 
pre-metastatic niche in different organs 
Exosomes, Microvesicles 193, 194
Modulating bone marrow-derived cells to generate a pro-vascular phenotype Exosomes 175
Induce immune suppression favoring tumor escape mechanisms Exosomes, Microvesicles 195- 197
Liver disease 
Cross-talk and horizontal transfer of miRNA between hepatocytes and 
monocytes  
Exosomes, Extracellular 
vesicles 
3, 98
Mediate intercellular communication between hepatocellular carcinoma cells Extracellular vesicles 198
Neurodegenerative disease 
Parkinson disease: Transfer of ɑsyn and inducing autophagy Exosomes 199
Regenerative and protective functions 
Human mesenchymal stem cell-derived EVs protected against glycerol or 
cisplatin-induced kidney injury
Extracellular vesicles 200,201
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Table 4: Overview of extracellular vesicle isolation techniques 
*PA: protein aggregates; ₸ LPP: lipoprotein particles; ɸ Non-selectivity can be advantage in case that the researchers/clinicians
are interested in isolating whole population of EVs and can be a disadvantage when isolation of a subset of EVs is of interest; ɣ to
proceed with imaging and characterization, it is necessary to dissolve the silicon nanowire in PBS buffer overnight.
Isolation Method (basic 
principal) 
Indication Advantages Disadvantages 
Ultracentrifugation 
(sedimentation based on 
size and density) 
Large volume of biofluids Most widely used standardized 
method, Can be combined 
with size exclusion and 
sucrose gradient method 21 
Low efficiency, Long protocol, Costly,  
Recovery dependent on rotor k factor and 
viscosity and sedimentation efficiency 
21,74, risk of contamination/co 
precipitation with viruses 23, PA* 21, and 
LPP₸  202 
Size exclusion (filtration+ 
chromatography) 
Large volume of biofluids, 
Can be combined with Nano-
membrane ultrafiltration 
concentrators 9 
Feasible, Inexpensive, 
Non-selectivity ɸ 
Does not concentrate the EVs, Forcing 
EVs through filters may cause 
deformation and breakup of large 
vesicles 24 
Immune affinity 
isolation  
(antibody against specific 
EVs surface proteins) 
High purity isolation of EVs, 
Isolation of sub-set of EVs, 
Isolation of EVs from viruses 
and LPP₸  
High specificity and 
selectivity 203,  Isolating 
special sub-set of EVs and 
negative selection 21,23, Easy to 
be coupled with beads and low 
speed centrifugation 
Cross reactivity of antibody, Costly, Low 
yield 78, Expensive equipment 
Microfluidic techniques 
(trapping EVs 
in micro channels) 
Low volume of input 
biofluids 
Can be combined by immune 
affinity methods 204 
Early stage of development, Low 
throughput, Lack of evidence regarding 
efficiency and downstream clinical 
utility in comparative studies, channel 
blocking. 
Polymeric precipitation 
methods (Reduce EV 
solubility and drive 
precipitation by 
dissolving polymers) 
Both low and high volume of 
input biofluids 
Technically not sensitive, 
Efficient isolation, High yield 
of EV recovery and EV-
associated RNA 9, Efficiency 
in clinical studies, Can be 
combined by immune affinity 
methods to increase purity 9,23 
Cannot appreciably purify EVs from a 
protein mixture and viruses unless 
coupled with immune affinity methods23 
Sieving methods 
(Deriving filtration by 
pressure or 
electrophoresis) 205 
Very low amount of input 
material (3ul-4ul) and rapid 
isolation 
Shorter separation time 
compared to size exclusion 205 
Low exosome recovery, Not suitable for 
large volume of biofluid, Lack of 
comparative studies and validation on 
clinical samples 204  
Porous structures 
(Capturing EVs through 
porous microstructures 
based on ciliated 
micropillar structure) 206 
Selectively trap particles in 
the range of 40-100 nm based 
on the research question 
Fast trapping Not suitable for isolation of larger 
particles, Not validated with clinical 
samples, Not suitable for handling large 
volume of biofluids, No analysis of cargo 
or comparative study available 204, Time 
consuming to characterize the EVs 
isolated based on this method ɣ 204 206 
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Table 5: Factors that affect the biomarker concordance during the course of the disease 
Causal factors Examples of the effect of the causal factor in EV-biomarker 
concordance 
References 
Clinical and biological 
Circadian exosomal marker expression Circadian exosomal expression of renal thiazide NaCl 
cotransporter and prostasin in urinary exosomes 
207
Change of exosomal cargo in different course 
of disease 
Changes in the miRNA-cargo content within EVs as a 
mechanism influencing bone metastatic colonization 
100
Heterogeneity in tumor microenvironment 
and tumorigenesis mechanisms 
40% of all breast cancers contain hypoxic microenvironments 
that produce EVs with specific signature (contains miRNA-
210) 
46, 208
Choosing the most clinically relevant 
biomarker 
mRNA transcript levels and corresponding protein showed 
marked differences in side by side measurements 
209
Individual variability (age, gender, genetic 
factors, ethnicity) 
Both qualitatively and quantitatively, the protein content of 
EVs showed gender specificity in renal tubule-specific 
responses in infected rats; 
EVs isolated from prostate cancer tumors showed ethnically 
and tumor-specific signatures 
91, 93, 210 
Diet factors EVs derived from palmitate-treated cells were enriched in 
palmitate and transferred the deleterious effect of palm oil to 
muscle cells 
95
Physical activity Physical exercise induces rapid release of exosome 
subpopulation of  extracellular vesicles into the circulation 
96
Variation in signature of different 
subpopulation of EVs 
Deep sequencing data showed the LIM1863 cells release 
different subpopulation of EVs harboring specific miRNA 
signature 
99
Difference between animal models and 
human studies 
Differential expression level of miRNA-122 in alcoholic 
hepatitis mouse model and human subjects with alcoholic 
hepatitis 
47
Technological, analytical and sample handling 
factors 
Difference in detection frequency of different 
techniques 
Differences in detection frequency of IDH1 mutation copy 
number in CSF of patients with Galioblastoma by BEAMing 
and Droplet Digital PCR Analysis 
67
Increasing time between venipuncture and 
centrifugation 
Induce rapture of EVs 211
Limitation in type of biomarkers miRNA biomarkers and protein biomarkers showed reduced 
sensitivity compared to combination of miRNA/proteins for 
pancreatic cancer diagnostics 
61
Collection, storage, and preservation of EVs Freezing at -20°C caused a major loss in urinary EVs in 
contrast to storing at -80°C which lead to complete recovery of 
EVs compared to fresh urine, vortexing after thawing increase 
exosome recovery 
212
High throughput sensitivity, dynamic range, 
and cost effectiveness 
RNA-seq provide broader dynamic range compared to 
microarray 
213
Choice of anticoagulant for plasma samples Heparin can cause false negative PCR reads 214
Challenges in accurate measurement of cargo Agilent Bioanalyzer small RNA kit is less accurate in 
quantifying miRNA after isolation of EVs, since presence 
ribosomal RNAs are not consistent in EVs 
88, 147
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Table 6: Examples of EV-associated miRNA dysregulation detected in human disease 
Differentially 
expressed 
miRNAs 
Disease Biofluid Controls Type of EVs Isolation 
methods 
Spike-
in/endogenous 
controls 
Ref Independent 
confirmation 
study 
miR-21 Increased in 
Hepatocellular 
Carcinoma 
Serum Healthy 
controls/Chronic 
hepatitis B 
Exosomes Total Exosome 
Isolation 
Reagent 
(Invitrogen) 
U6 snRNA 135 None 
miR-192, miR-
30a, miR-122 
Increased in 
alcoholic 
hepatitis 
Plasma Healthy controls EVs Filtration/ 
ExoQuick 
(System 
Biosciences) 
miR-15a, 
spiked in Cel-
39 
47 miR-1223 
A multi-
biomarker panel 
(RNU6-1/miR-
16-5p, miR-25-
3p/miR-320a,
let-7e-5p/miR-
15b-5p, miR-
30a-5p/miR-
324-5p, miR-
17-5p/miR-194-
5p)
Increased in 
locally 
advanced 
esophageal 
adeno-
carcinoma 
Serum Healthy controls/ 
Barrett's 
esophagus 
Exosomes ExoQuick Global 
normalization 
136 None 
miR-126, miR-
199a 
Increased levels 
inversely 
predict 
cardiovascular 
events 
Plasma Patients with 
stable coronary 
artery disease. 
Micro-
vesicles 
Ultracentrifuga
tion 
spiked in 
Cel-miR-39 137 None 
miR-375, miR-
141p 
Increased in 
prostate cancer 
Urine Healthy controls Exosomes, 
Micro-
vesicles 
ExoMir 
extraction 
snoRNAs 
(RNU44 and 
RNU48), Cel-
miR-39 
138 miR-375140 
let-7a, miR-
1229, miR-
1246, miR-150, 
miR-21, miR-
223, miR-23a 
Increased in 
colon cancer 
Serum Healthy control Exosomes Ultracentrifuga
tion 
Global 
normalization
,  miR-451 
59 None 
let-7f, miR-20b, 
miR-30e-3p 
Decreased in 
non-small cell 
lung cancer 
Plasma Healthy controls Micro-
vesicles 
Immuno 
magnetic 
beads 
miR-142-3p 
and miR-30b 
139 None 
miR-1290, 
miR-375 
Higher levels 
associated with 
poor survival 
Plasma castration-
resistant prostate 
cancer patients 
Exosomes ExoQuick miR-30a-5p, 
miR-30e-5p 
140 None 
miR-29c Negatively 
associated with 
early renal 
fibrosis in lupus 
nephritis 
Urine Healthy controls/ 
non-lupus 
chronic kidney 
disease 
Exosomes Ultracentrifuga
tion 
GAPDH 
(mRNA), 
RNU6 
141 None 
39	
Box1- Classification of extracellular vesicles 
Historically, EV classification was based on cellular origin. However, EVs can be more 
accurately categorized on the basis of their biogenesis. 
Oncosomes: tumor microvesicles that transmit signaling complex between cells. 
Ectosomes: vesicles secreted by human polymorphonuclear leukocytes	
Microparticles: vesicles originated from pellets 
Dexosomes: vesicles released from dentritic cells	
Texosomes: vesicles derived from tumor cells	
EV classification based on mode of biogenesis 
*ESCRT: Endosomal sorting complex required for transport complex, MFGE8: milk fat globule-
EGF factor 8 protein, TSG101: tumor susceptibility gene 101, HSPs: heat shock proteins
Exosomes
•Origin:	budding	of	inter
luminal	multivesicular
bodies	of	endosomal
pathways
•Size:	30-100	nm
•Surface	markers:
Tetraspanins	(CD61,	CD
81,CD82,	CD9),	ESCRT
components,	TSG101,
Flotillin 1	and Flotillin 2,
HSPs,	ALIX,	MFGE8
Microvesicles
•Origin:	Outward
budding	of	plasma
membrane
•Size:	50-1000	nm
•Surface	markers:
AnnexinV,	Integrins,
CD40	ligand
Apoptotic	bodies
•Origin:	Outward
budding	of	plasma
membrane	in	apoptotic
cells
•Size:50-5000	nm
•Surface	Markers:
AnnexinV,	particularly
enriched	in
phosphatidylserin
40	
Figure 1- Exosome biogenesis and secretion- Exosomes are generated from multivesicular 
bodies (MVBs) of the endosomal system. Early endosomes formed after endocytosis and from 
MVBs in which cargo is packed in the exosomes by inward budding of the membrane. ESCRT 
machinery, mono-ubiquitination and the  lipid raft and segregation into microdomains by 
ceramide has been described as facilitators to the exosome biogenesis. MVBs can merge with 
lysosomes resulting in degradation of the cargo or MVBs can merge with the plasma membrane 
which results in exosome release. This process is regulated by a by Rab GTPases. Exosomes 
contain different cargoes including Rab proteins, ALIX, MHC molecules, clatherins and 
transferrin receptors.   
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Figure 2- Volume of EVs publications. The bar chart shows the number of publications in 
general topic of EVs and related to the search term “extracellular vesicles OR exosomes OR 
microvesicles AND biomarkers” that were listed on PubMed between January 1, 2004 and 
December 31, 2015. 
42	
Figure 3- The EV biomarker workflow. An illustration of a pipeline in taking an EV-associated 
biomarker from bench to bedside  
43	
Figure	4-	Frame work of integrating omics data and system biology approach in EV biomarker 
studies 	
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